A cross-scanner and cross-tracer deep learning method for the recovery of standard-dose imaging quality from low-dose PET

[1] Beer AJ(2011)Radionuclide and hybrid imaging of recurrent prostate cancer The lancet oncology. 12 181-191

[2] Eiber M(2015)PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study The lancet oncology. 16 284-292

[3] Souvatzoglou M(2011)Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Lancet neurology. 10 424-435

[4] Schwaiger M(2015)Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study Lancet. 385 S91-12

[5] Krause BJ(2009)The ALARA concept in pediatric oncology Pediatric radiology. 39 1142-485

[6] Moskowitz AJ(2017)Effective dose estimation for oncological and neurological PET/CT procedures EJNMMI research. 7 37-1518

[7] Schoder H(2018)Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care Journal of Nuclear Medicine. 59 3-1036

[8] Yahalom J(2017)History and future technical innovation in positron emission tomography Journal of Medical Imaging. 4 41-14

[9] McCall SJ(2020)Why ultrafast is ultra-good Physics World. 33 473-623

[10] Fox SY(2017)Pushing the limits in time-of-flight PET imaging IEEE Transactions on radiation and plasma medical sciences. 1 1511-1390

[1] Beer AJ(2011)Radionuclide and hybrid imaging of recurrent prostate cancer The lancet oncology. 12 181-191

[2] Eiber M(2015)PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study The lancet oncology. 16 284-292

[3] Souvatzoglou M(2011)Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Lancet neurology. 10 424-435

[4] Schwaiger M(2015)Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study Lancet. 385 S91-12

[5] Krause BJ(2009)The ALARA concept in pediatric oncology Pediatric radiology. 39 1142-485

[6] Moskowitz AJ(2017)Effective dose estimation for oncological and neurological PET/CT procedures EJNMMI research. 7 37-1518

[7] Schoder H(2018)Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care Journal of Nuclear Medicine. 59 3-1036

[8] Yahalom J(2017)History and future technical innovation in positron emission tomography Journal of Medical Imaging. 4 41-14

[9] McCall SJ(2020)Why ultrafast is ultra-good Physics World. 33 473-623

[10] Fox SY(2017)Pushing the limits in time-of-flight PET imaging IEEE Transactions on radiation and plasma medical sciences. 1 1511-1390